
We are a biotechnology company engineering and developing innovative, highly-selective, immune cell modulating biotherapeutics to address unmet medical needs in patients with inflammatory diseases and cancer. Our proprietary AbiLeap™ discovery engine combines massively parallel, continuously learning artificial intelligence (AI) with an extensive proprietary database of therapeutic antibody sequences and antigen-antibody interactions to generate fully-human antibodies with exquisite selectivity and developability. Moreover, AbiLeap™ can generate novel antibodies with particular functions such…

Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Estimated OwnershipPrivate